Chimeric Therapeutics Ltd. ( (AU:CHM) ) has issued an update.
Chimeric Therapeutics announced that the University of Chicago Medicine has joined its Phase 1/2 clinical trial for CHM CDH17, a pioneering anti-CDH17 CAR-T cell therapy. This trial targets advanced colorectal, gastric, and intestinal neuroendocrine cancers, with the goal of determining the Phase 2 dose and evaluating safety and response rates. The inclusion of a prestigious institution like UChicago Medicine highlights the potential impact of this therapy on the treatment of gastrointestinal tumors.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics is an Australian clinical-stage cell therapy company specializing in innovative cancer treatments. It boasts a diversified portfolio of autologous CAR T and allogeneic NK cell therapies targeting multiple oncology disease areas, with four clinical-stage programs.
Average Trading Volume: 3,014,500
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$11.03M
For detailed information about CHM stock, go to TipRanks’ Stock Analysis page.